European Association of Nuclear Medicine

Perspective Therapeutics Announces First Patient Dosed in Phase 1/2a Study of [(212)Pb]VMT-α-NET for Treatment of Advanced SSTR2-Positive Neuroendocrine Tumors

Retrieved on: 
Wednesday, November 8, 2023
Radiation therapy, Standard of care, DOTATATE, NYSE, Washington University in St. Louis, CATX, European Association of Nuclear Medicine, Mallinckrodt Institute of Radiology, PRRT, Glomus tumor, Tissue, Washington University School of Medicine, SSTR2, European Association for the Study of the Liver, NETS, TAT, Safety, Fast track (FDA), Therapy, Patient, Pharmaceutical industry, Radiology

The trial is a multi-center, open-label dose escalation, dose expansion study of [212Pb]VMT-α-NET in patients who have not received prior peptide receptor radionuclide therapy (PRRT).

Key Points: 
  • The trial is a multi-center, open-label dose escalation, dose expansion study of [212Pb]VMT-α-NET in patients who have not received prior peptide receptor radionuclide therapy (PRRT).
  • “We are proud of our team’s commitment and progress in bringing our radionuclide therapy to patients suffering from these difficult-to-treat neuroendocrine tumors,” said Thijs Spoor, Chief Executive Officer of Perspective Therapeutics.
  • “The development of Perspective’s [212Pb]VMT-α-NET targeted alpha particle therapy is an important next step in the evolution of treatments for SSTR2-expressing tumors.
  • We are excited to participate in the trial.”
    “We are excited about our collaboration with investigators from top-tier research centers who are evaluating [212Pb]VMT-α-NET in patients with intractable SSTR2-expressing neuroendocrine tumors,” said Markus Puhlmann, Chief Medical Officer of Perspective Therapeutics.

United Imaging Healthcare debuts Next-Generation PET/CT Systems, the uMI Panorama Family, and the Integrated Molecular Technology Platform at EANM

Retrieved on: 
Thursday, September 21, 2023
Yale University, CE, IPO, University of California, Davis, NX, University, Moses Austin, MI, NEMA, Peking Union Medical College Hospital, EANM, BRAIN, Deep learning, NCI-designated Cancer Center, PET, Brain, Research, Nuclear medicine, Radiopharmaceutical, Washington University in St. Louis, Gold standard, Umi, Huntsman Cancer Institute, Radiation, European Association of Nuclear Medicine, UC, Patient, Molecular imaging, Fudan University, DOI, PET/CT, Artificial intelligence, AdventHealth Celebration, Panorama, Neoplasm, FDA, FOV, AI, Zhongshan Hospital, Medical imaging

VIENNA, Sept. 21, 2023 /PRNewswire/ -- United Imaging Healthcare, a global leader in advanced medical imaging and radiotherapy equipment, introduces its next-generation PET/CT systems, the uMI Panorama™, and the integrated molecular technology platform named uExcel, at the European Association of Nuclear Medicine (EANM) 2023 annual meeting taking place from September 9-12 in Vienna, Austria. As the sponsor of the "EANM Young Authors' Award" and "EANM Technologist Award" this year, United Imaging is playing a significant role in driving innovation in the field of molecular imaging and nuclear medicine on a global scale.

Key Points: 
  • The new wide-bore uMI Panorama is a family of products that includes the uMI Panorama, the uMI Panorama GS, and the NeuroEXPLORER.
  • The uMI Panorama GS, deriving its name from the term "Gold Standard", was born to set the gold standard in molecular imaging and revolutionize whole-body PET imaging.
  • In tandem with uMI Panorama, the uExcel, is an advanced molecular imaging technology platform meticulously integrated with both hardware and software components.
  • (Note: The uMI Panorama and the uMI Panorama GS are CE pending, not commercially available yet.

Molecular Partners Presents New Data on its Radio DARPin Therapy (RDT) Platform at the EANM 2023 Annual Meeting

Retrieved on: 
Wednesday, September 13, 2023
DARPin, Partnership, AACR, Therapy, EANM, Half-life, RDT, Nuclear medicine, Delta, Radiation, DLL3, European Association of Nuclear Medicine, Novartis, Molecular Partners, Engineering, Kidney, Neoplasm, Radio, Pharmaceutical industry, Vaccine, CONCORD

These data will be presented at the European Association of Nuclear Medicine (EANM) Annual Meeting, held September 9–13 in Vienna, Austria and can be accessed here .

Key Points: 
  • These data will be presented at the European Association of Nuclear Medicine (EANM) Annual Meeting, held September 9–13 in Vienna, Austria and can be accessed here .
  • The data show the ability of Molecular Partners to substantially increase tumor uptake of RDT candidates through an adjustment of systemic half-life, achieved by binding to the common blood protein serum albumin.
  • With today’s data we show that tuning of half-life can substantially impact the tumor uptake of our Radio DARPins,” said Patrick Amstutz, Ph.D., CEO of Molecular Partners.
  • Molecular Partners continues to progress its RDT platform and portfolio of projects, both in-house and in partnership with Novartis.

NUCLIDIUM to Present Data from Three Clinical-Ready Precision Oncology Programs at the 36th Annual EANM Congress

Retrieved on: 
Tuesday, September 5, 2023
Science, Radiology, Biotechnology, Research, Pharmaceutical, Oncology, Health, Clinical Trials, NETS, 18F, Half-life, EANM, PSMA, Survival, Cancer, Pharmacokinetics, University Hospital of Basel, FAP, Heterotrimeric G protein, Nuclear medicine, Radiopharmaceutical, Doctor of Philosophy, University Hospital of Zürich, Glomus tumor, European Association of Nuclear Medicine, Patient, PET/CT, Entrepreneurship, European Association for the Study of the Liver, Prostate cancer, Medical imaging

NUCLIDIUM today announced the presentation of pre-clinical and clinical translation data from three of the company’s precision oncology programs targeting epithelial tumours (KaliosTM), neuroendocrine tumours (TraceNETTM) and prostate cancer (NuriProTM) at the upcoming 36th Annual Congress of the European Association of Nuclear Medicine (EANM), 09-13 September 2023.

Key Points: 
  • NUCLIDIUM today announced the presentation of pre-clinical and clinical translation data from three of the company’s precision oncology programs targeting epithelial tumours (KaliosTM), neuroendocrine tumours (TraceNETTM) and prostate cancer (NuriProTM) at the upcoming 36th Annual Congress of the European Association of Nuclear Medicine (EANM), 09-13 September 2023.
  • The data, presented in two oral presentations and a poster presentation, support the advancement of these three programs into clinical translation.
  • The programs are part of NUCLIDIUM’s comprehensive pipeline of copper-based radiotheranostics based on its flexible CuTraceTM platform.
  • The positive pre-clinical data for the diagnostic candidates from three of our programs and the preparation for clinical translation represent an important step for NUCLIDIUM.

Perspective Therapeutics to Present Clinical and Preclinical Data at the 36th Annual Congress of the European Association of Nuclear Medicine

Retrieved on: 
Monday, August 28, 2023
Neuroblastoma, Abstract, MBBS, Metastasis, EANM, Glomus tumor, Targeted molecular therapy for neuroblastoma, MBA, DNB, Nuclear medicine, PET-CT, Perspective, European Association of Nuclear Medicine, CATX, MD, Patient, Molina Healthcare, FMRI, Cancer, Therapy, NYSE, Targeted alpha-particle therapy, Pharmaceutical industry, Safety, IOWA

RICHLAND, WASH. & CORALVILLE, IOWA, Aug. 28, 2023 (GLOBE NEWSWIRE) --  – Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), today announced that it will present new clinical and preclinical data for 212Pb-VMT-α-NET, a Targeted Alpha-Particle Therapy, at the upcoming 36th Annual Congress of the European Association of Nuclear Medicine (EANM).

Key Points: 
  • RICHLAND, WASH. & CORALVILLE, IOWA, Aug. 28, 2023 (GLOBE NEWSWIRE) --  – Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), today announced that it will present new clinical and preclinical data for 212Pb-VMT-α-NET, a Targeted Alpha-Particle Therapy, at the upcoming 36th Annual Congress of the European Association of Nuclear Medicine (EANM).
  • “Our team at Perspective Therapeutics continues to work diligently to advance much needed targeted alpha therapy using 212Pb,” said Thijs Spoor, Chief Executive Officer at Perspective Therapeutics.
  • “We are particularly excited about the early clinical results from 212Pb-VMT-α-NET in patients suffering from different types of difficult-to-treat neuroendocrine tumors.
  • The data showed that fractionated doses of [212Pb]VMT-α-NET provided greater benefit than single dose administration of [212Pb]VMT-α-NET.

United Imaging Healthcare Attends European Association of Nuclear Medicine Congress With uEXPLORER®, The World's First Total-Body PET/CT

Retrieved on: 
Monday, October 24, 2022
Congress, Yale University, UIH, FOV, Nuclear medicine, Neurological disorder, PET-CT, Cardiology, IPO, NX, European Association of Nuclear Medicine, EANM, Lists of diseases, Technology, Molecular imaging, Marketing, Industry, Association, Umi, UC, Alzheimer's disease, PET/CT, Health, CEO, University of California, Davis, Neurodegeneration, PET, Degenerative disease, CTO, Solution, Medical imaging

BARCELONA, Spain, Oct. 24, 2022 /PRNewswire/ --United Imaging Healthcare (UIH), a global innovator in advanced medical imaging, debuts at the European Association of Nuclear Medicine (EANM) Congress recently in Barcelona with its groundbreaking PET/CT, uEXPLORER.

Key Points: 
  • BARCELONA, Spain, Oct. 24, 2022 /PRNewswire/ --United Imaging Healthcare (UIH), a global innovator in advanced medical imaging, debuts at the European Association of Nuclear Medicine (EANM) Congress recently in Barcelona with its groundbreaking PET/CT, uEXPLORER.
  • The system offers total-body dynamic scanning, allows ultra-low patient dose, and produces ultra-high image resolution, changing how whole-body PET/CT imaging has traditionally been performed.
  • Fresh off the heels of its IPO, the company hit another landmark, shipping its 20,000th global installation recently.
  • Now UIH has a well-equipped local team including marketing, training, and after-sales service in Europe.

Isoray Medical, Inc. and Viewpoint Molecular Targeting, Inc. Announce Investor Webcast on October 19, 2022 at 4:15 p.m. EDT

Retrieved on: 
Tuesday, October 18, 2022
Biotechnology, Radiology, Pharmaceutical, Health, LinkedIn, Mallinckrodt Institute of Radiology, Time, U.S. Securities and Exchange Commission, Private Securities Litigation Reform Act, Therapy, European Association of Nuclear Medicine, Review, Neoplasm, Neuroendocrine tumor, NYSE, Wilms' tumor, Seed, Twitter, Security (finance), Radiology, Multimedia, Viewpoint, Washington University in St. Louis, 8-K, Doctor of Philosophy, Association, Nuclear medicine, ISR, Toxicity, EDT, Clinical trial, European Association of Urology, Forward-looking statement, Peptide, Cancer, Medical imaging, IsoRay

Isoray, Inc., through its subsidiary, Isoray Medical, Inc., is the sole producer of Cesium-131 brachytherapy seeds.

Key Points: 
  • Isoray, Inc., through its subsidiary, Isoray Medical, Inc., is the sole producer of Cesium-131 brachytherapy seeds.
  • Learn more about this innovative Richland, Washington company and explore the many benefits and uses of Cesium-131 by visiting www.isoray.com .
  • Viewpoint Molecular Targeting is a radiopharmaceutical company developing precision oncology therapeutics and complementary diagnostic imaging agents.
  • These forward-looking statements (except as may be otherwise noted) speak only as of the date of this press release.

Telix Partnership Expands GE Healthcare Immuno-Diagnostics Offering to the Global Clinical Research Market

Retrieved on: 
Monday, October 17, 2022
LinkedIn, Congress, Australian Securities Exchange, Head, ICI, Lactic acid, Neoplasm, GE Healthcare, Thomas Edison, TGA, Association, Advertising, Cancer, Carbonic anhydrase, NYSE, Regulation of tobacco by the U.S. Food and Drug Administration, HIV disease progression rates, Company, Marketing, Industry, Nuclear medicine, Diversified Pharmaceutical Services, European Association for the Study of the Liver, Disclosure, FDA, Risk, Review, EANM, Research, Multimedia, Immunotherapy, Degenerative disease, Gallium, Veni, vidi, vici, PD-1, Ecosystem, Oxygen, View, ASX, Patient, European Association of Nuclear Medicine, Partnership, Food, TLX, United Kingdom, PET, Forward-looking statement, JAMA Network Open, Medical imaging, Pharmaceutical industry, Animal, Media, Telix

TLX250-CDx and [18F]-FLac complement GE Healthcare Pharmaceutical Diagnostics' pipeline of investigational non-invasive [18F]-CD8 and[18F]-Granzyme-B imaging tracers for use by pharmaceutical companies in clinical trials, with the potential to predict and monitor response to immunotherapy.

Key Points: 
  • TLX250-CDx and [18F]-FLac complement GE Healthcare Pharmaceutical Diagnostics' pipeline of investigational non-invasive [18F]-CD8 and[18F]-Granzyme-B imaging tracers for use by pharmaceutical companies in clinical trials, with the potential to predict and monitor response to immunotherapy.
  • Sanka Thiru, Global Business Leader, Immuno-Oncology, at GE Healthcare's Pharmaceutical Diagnostics business, said: "This partnership expands our pharmaceutical services offering, including our toolbox of investigational PET imaging diagnostics.
  • Telix and GE Healthcare will explore validation of [18F]-FLac for use in GE Healthcare's FASTlab, an automated PET radiochemistry synthesiser, widely used for onsite production of FDG6 and other PET tracers.
  • The Telix Pharmaceuticals and the Illuccix name and logo are trademarks of Telix Pharmaceuticals Limited and its affiliates all rights reserved.

Telix Partnership Expands GE Healthcare Immuno-Diagnostics Offering to the Global Clinical Research Market

Retrieved on: 
Monday, October 17, 2022
LinkedIn, Congress, Australian Securities Exchange, Head, ICI, Lactic acid, Neoplasm, GE Healthcare, Thomas Edison, TGA, Association, Advertising, Cancer, Carbonic anhydrase, NYSE, Regulation of tobacco by the U.S. Food and Drug Administration, HIV disease progression rates, Company, Marketing, Industry, Nuclear medicine, Diversified Pharmaceutical Services, European Association for the Study of the Liver, Disclosure, FDA, Risk, Review, EANM, Research, Immunotherapy, Degenerative disease, Gallium, Veni, vidi, vici, PD-1, Ecosystem, Oxygen, ASX, Patient, European Association of Nuclear Medicine, Partnership, Food, TLX, United Kingdom, PET, Forward-looking statement, JAMA Network Open, Medical imaging, Pharmaceutical industry, Animal, Media, Telix

Sanka Thiru, Global Business Leader, Immuno-Oncology, at GE Healthcare's Pharmaceutical Diagnostics business, said: "This partnership expands our pharmaceutical services offering, including our toolbox of investigational PET imaging diagnostics.

Key Points: 
  • Sanka Thiru, Global Business Leader, Immuno-Oncology, at GE Healthcare's Pharmaceutical Diagnostics business, said: "This partnership expands our pharmaceutical services offering, including our toolbox of investigational PET imaging diagnostics.
  • Telix and GE Healthcare will explore validation of [18F]-FLac for use in GE Healthcare's FASTlab, an automated PET radiochemistry synthesiser, widely used for onsite production of FDG6 and other PET tracers.
  • The Telix Pharmaceuticals and the Illuccix name and logo are trademarks of Telix Pharmaceuticals Limited and its affiliates all rights reserved.
  • CONTACT: Telix Investor Relations: Ms. Kyahn Williamson, Telix Pharmaceuticals Limited, SVP Corporate Communications and Investor Relations, Email: [email protected] ; GE Healthcare Media Contact: Debbie Leven / [email protected] , +44 7785 456999

GE Healthcare Introduces Omni Legend: A First-of-its-Kind All-Digital PET/CT System to Drive Efficiency, Enhance Diagnostics, and Deliver on Precision Medicine

Retrieved on: 
Sunday, October 16, 2022
Oncology, Health, Medical Devices, Neurology, Radiology, Cardiology, Biotechnology, Omni, LinkedIn, Efficiency, Protocol, Instagram, LED, Thomas Edison, CT scan, Association, CEO, Health, Calibration, Gallium, Challenge, Dynamics, Precision, News, NEMA, Cardiology, NYSE, GE Healthcare, Twitter, Annual general meeting, Artificial intelligence, Software, Nuclear medicine, CE, European Association of Nuclear Medicine, Gallium-68 generator, Movement, Deep learning, Diagnosis, EANM, Maimonides, Collection, Technology, Molecular imaging, Technion Faculty of Electrical Engineering, Ecosystem, Artifact, Sale, BGO, Technion – Israel Institute of Technology, Patient, Insight, CT, Rambam Health Care Campus, PET, Medical imaging, Medical device, Pharmaceutical industry, Facebook, PET/CT

At the European Association of Nuclear Medicine (EANM) Annual Meeting, GE Healthcare proudly introduces Omni Legendi, the first system on its all-new, all-digital PET/CT platform.

Key Points: 
  • At the European Association of Nuclear Medicine (EANM) Annual Meeting, GE Healthcare proudly introduces Omni Legendi, the first system on its all-new, all-digital PET/CT platform.
  • For more information about GE Healthcares new Omni PET/CT platform and Omni Legend system, visit gehealthcare.com .
  • GE Healthcare is the $17.7 billion healthcare business of GE (NYSE: GE).
  • ii Omni Legend 32 cm has up to 2.2 increase in system sensitivity as compared to Discovery MI 25 cm.